IMMUNOSUPRESIVE THERAPY (IST) FOR MYELODYSPLASTIC SYNDROME (MDS) IN
A TERTARY MEDICAL CENTER IN NORTHEAST OF MEXICO. SINGLE EXPERIENCE
IN 5 YEARS.
Guillermo Sotomayor Duque
I
nstituto Mexicano del Seguro Social, Monterrey, Mexico
I
NTRODUCTION: Myelodysplastic syndromes (MDS) are a heterogeneous group of
hematological pathologies of clonal origin, characterized by ineffective hematopoiesis,
peripheral cytopenias, and a variable risk of transformation to acute leukemia. Within its
pathophysiology, genetic alterations play a key role. Extrinsic factors, such as stromal
abnormalities and T-cell dysregulation, also contribute significantly to the pathology of MDS.
We aimed to document clinical outcomes of patients treated with IST in our center.
MATERIAL AND METHODS: A retrospective, descriptive study was conducted from January
2013 to November 2018. Patients with MDS diagnosed according to the WHO criteria.
Measures of central tendency, frequencies with percentages, analysis of survival with Kaplan-
Meier curves were carried out.
RESULTS: A total of 53 patients were included, median age 70 years (28-85) with a
predominance of males (51%).
Regarding immunosuppressive therapy; corticosteroids (66%), cyclosporine (47.2%), rATG
(18.9%), thalidomide (18.9%), mycophenolate (15.1%), tacrolimus (5.6%) were used.
Androgen therapy was used in 54.7% of the patients. There was a transfusion requirement in
58.5% of the patients.
The global response achieved was 56.3% (complete hematology response 20.5%, partial
response 35.8%),stable disease was 30.2% and 13.4% without response.
The median time to reach some type of response was 2 months (range 0-5) and the duration
of responde was 6 months (range 0-185). There was progression to
AML in a total of 7 patients (13.2%). Only 3 patients patients were subjected to HSCT.
Median overall survival was 18 months (range 1-194) and OS at five years was 76%.
POSTER 22
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES